Trichostatin A | 曲古柳菌素A | TSA | HDAC Class I/II Inhibitor

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	EGFR,HER2	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													99%
Panobinostat			++++ HDAC (Reh cells), IC50: 20 nM HDAC (MOLT-4 cells), IC50: 5 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												Nrf2,NF-κB	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											NF-κB,p53	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			99%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			97%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cell Line HT-3 cells ME-180 cells SiHa cells mouse primary hepatocytes IMR90 cells MG-63 cells NSCLC cell lines HeLa cells	Concentration	Treated Time	Description	References
HT-3 cells	100 nM	24 h	SLIT2 gene expression showed minimal reactivation after TSA treatment	Mol Cancer. 2006 May 15;5:16.
ME-180 cells	100 nM	24 h	SLIT2 gene expression was reactivated after TSA treatment	Mol Cancer. 2006 May 15;5:16.
SiHa cells	100 nM	24 h	SLIT2 gene expression was not reactivated after TSA treatment	Mol Cancer. 2006 May 15;5:16.
mouse primary hepatocytes	1 μM		To investigate the role of SIRT5 in regulating protein malonylation in hepatocytes, results showed that SIRT5 deficiency led to a significant increase in protein malonylation levels in hepatocytes.	Mol Cell. 2015 Jul 16;59(2):321-32.
IMR90 cells	100 nM	10 days	Trichostatin A (TSA) treatment significantly decreased accumulation of CCFs in senescent cells and strongly reduced the expression of key SASP genes.	Genes Dev. 2020 Mar 1;34(5-6):428-445.
MG-63 cells	10 nM	24 h	As a positive control for histone acetylation, TSA treatment significantly increased histone acetylation levels in MG-63 cells.	Front Immunol. 2023 May 31;14:1138539.
NSCLC cell lines	300 nM	18 h	To evaluate the effect of TSA on SULF2 expression, partial restoration of SULF2 expression was observed in some cell lines	Oncogene. 2012 Sep 13;31(37):4107-16.
HeLa cells	100 or 300 ng/ml	4-24 h	TSA treatment reversibly increased the acetylation level of histone H4 globally and at these initiation sites, promoting a more dispersive pattern of initiations.	Nucleic Acids Res. 2005 Jan 13;33(1):325-36.

Species C57BL/6N mice Mice NOD/SCID mice Mice	Animal Model ICCA tumor model Not3 knockout mice A549-luci subcutaneous transplantation model C57BL/6 mice	Administration	Dosage	Frequency	Description	References
C57BL/6N mice	ICCA tumor model	Intraperitoneal and subcutaneous injection	0.5 mg/kg	Once a week for five weeks	Evaluate the effect of TSA and IFN-α2 combination therapy on ICCA tumor development	J Exp Clin Cancer Res. 2024 May 30;43(1):152
Mice	Not3 knockout mice	Drinking water	0.71% w/v	1 week	HDAC inhibitors VPA and TSA rescued the impaired heart function in not3+/? mice, restoring cardiac contractility.	Cell. 2010 Apr 2;141(1):142-53
NOD/SCID mice	A549-luci subcutaneous transplantation model	Intraperitoneal injection	0.5 mg/kg	Every 3 days until the mice died	To evaluate the inhibitory effect of Trichostatin A combined with ibuprofen on cancer progression	Br J Cancer. 2020 Sep;123(5):730-741
Mice	C57BL/6 mice	Intraperitoneal injection	0.5 mg/kg	1 day before and simultaneously with APAP administration, lasting 48 hours	Trichostatin A (TSA) significantly reduced APAP-induced CCF and SASP expression and decreased oxidative stress and inflammation.	Genes Dev. 2020 Mar 1;34(5-6):428-445.

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

A2780	0.05-2 μM	Growth Inhibition Assay	10/24/48 h	mediates growth arrest in a concentration- and time-dependent manner	24223801
A431	2/10/50/100nM	Apoptosis Assay	48h	inhibits the cell growth	25371069
A431	50nM	Function Assay	2/6/12/24h	activates p21 and inhibits ATF3 expression	25371069
A549	1-10μM	Growth Inhibition Assay	24h	IC50 of 3.2μM	25169491
A549	0.1-1μM	Growth Inhibition Assay	48h	IC50 of 0.28μM	25169491
A549	0.01-0.9μM	Growth Inhibition Assay	72h	IC50 of 0.06μM	25169491
A549	0.25/0.5/1 μM	Growth Inhibition Assay	24/48/72 h	inhibits the cell growth in concentration and time-dependent manner	23867991
A549	0.5/1 μM	Apoptosis Assay	48 h	induces cell apoptosis	23867991
A549	250 nM	Growth Inhibition Assay	6-72 h	causes a greater inhibitory effect combine with TXT or erlotinib	22994780
ACP02	250/350/500nM	Growth Inhibition Assay	24h	decreases cell viability of approximately 70 % at 250 nM	24668547
ACP03	250/350/500nM	Growth Inhibition Assay	24h	decreases cell viability of approximately 70 % at 250 nM	24668547
AGS	0.015-1 μM	Growth Inhibition Assay	72 h	induces cell death concentration dependently	23745024
ARN8	0.05-2 μM	Function Assay	24 h	reduces the induction of p53-dependent genes by Nutlin-3	23470540
CA46	3/6/12/24/48 nM	Growth Inhibition Assay	48 h	inhibits the cell proliferation at 24 and 48 nM	24064951
Caco-2	1 µM	Function Assay	24 h	decreases SERT protein expression	23195070
CNE2	100-600nM	Growth Inhibition Assay	24/48/72h	inhibits the proliferation in a time- and dose-dependent manner	24969901
ECC1	500 nM	Function Assay	5 d	induces L1CAM expression co-treatment with 5-AzaC	23530769
ECC-1	100 nM	Growth Inhibition Assay	24 h	increases the proportion of apoptotic nuclei to 35%	23028803
EN1	500 nM	Function Assay	5 d	induces L1CAM expression co-treatment with 5-AzaC	23530769
H1299	1 μM	Growth Inhibition Assay	24/48/72 h	increases cell death after 24h	23916609
H1299	0.25/0.5/1 μM	Growth Inhibition Assay	24/48/72 h	inhibits the cell growth in concentration and time-dependent manner	23867991
H1299	0.5/1 μM	Apoptosis Assay	48 h	induces cell apoptosis	23867991
H1299	0.33–1 µM	Function Assay	24/48 h	increases E-cadherin protein levels dose dependently	23461975
H1299	0.5 μM	Function Assay	48 h	inhibits the migratory potential combine with silibinin	23461975
H1299	0.5 μM	Function Assay	48 h	inhibits the invasiveness combine with silibinin	23461975
HASMCs	0-500 nM	Function Assay	6 d	down-regulates the expression of HADC and cell viability	23518467
HCT1	0.2/1.0/5.0 μM	Growth Inhibition Assay	12/24/36/48 h	induces cell death in concentration- and time-dependent manner	23770000
HCT116	0.2 μM	Growth Inhibition Assay	12 h	enhances cell apoptosis induced by radiation	24122231
HEC1A	500 nM	Function Assay	5 d	induces L1CAM expression co-treatment with 5-AzaC	23530769
HEC-1A	100 nM	Growth Inhibition Assay	24 h	increases the proportion of apoptotic nuclei to 39%	23028803
HEK 293	0.7μM	Function Assay	24h	enhances ENaC acetylation and increases ENaC abundance in the total cell lysate and at the cell surface	25787079
HEK293	1 µM	Function Assay	18 h	inhibits the kalirin-7-mediated recruitment of synphilin-1 aggregates into aggresomes	23284848
HEL	0.5 μM	Function Assay	24 h	decreases the enzyme activity of HDACs co-treatment with curcumin	23430957
HeLa	250nM	Function Assay	16h	increases CYP1A1 mRNA expression	25116688
HeLa	2μM	Growth Inhibition Assay	48h	decreases cell viability about 25%	24846135
HeLa	1mM	Function Assay	0.5h	abolishes the total HDAC activity	24707474
HeLa	100 nM	Growth Inhibition Assay	24 h	IC50 of 100nM	23165748
HeLa	40 nM	Growth Inhibition Assay	48 h	IC50 of 40nM	23165748
HeLa	20 nM	Growth Inhibition Assay	72 h	IC50 of 20nM	23165748
HeLa	10/30/50 nM	Growth Inhibition Assay	72 h	increases the number of MMP (ΔΨm) loss cells dose dependently	23165748
HL60	1 μM	Apoptosis Assay	24 h	induces cell death	23400519
HL60	150-350 nM	Growth Inhibition Assay	24 h	increases cell apoptosis when concentrations higher than 250 nM	22753739
HLEB3	0.2 μM	Growth Inhibition Assay	48 h	suppresses cell proliferation through suppressing the PI3K/Akt, p38MAPK and ERK1/2 signaling pathways	24157878
HLEB3	0.4/0.8 μM	Growth Inhibition Assay	48 h	induces cell apoptosis	24157878
HMEC-1	300nM	Function Assay	24h	increases expression of VEGFR3 mRNA	24710631
hMSCs	6.25 nM	Function Assay	24 h	stabilizes Histone Acetylation and the Expression of Pluripotent Genes	24312356
HT29	180 nM	Growth Inhibition Assay	72 h	IC50 of 180 nM	24368265
HTK	400 nM	Function Assay	72 h	inhibits TGF-β–Induced Myofibroblast Differentiation	23284002
HTK	100-800nM	Function Assay	72 h	blocks TGF-β–Induced ROS and H2O2 Accumulation	23284002
Huh7	0.1/0.5/1.0 μM	Function Assay	24h	suppresses YTHDC2 gene expression	24269672
Huh7	1 μM	Growth Inhibition Assay	24 h	reduces about 20% viability	23643933
K562	0.5 μM	Function Assay	24 h	decreases the enzyme activity of HDACs co-treatment with curcumin	23430957
K562	1 μM	Apoptosis Assay	24 h	induces cell death	23400519
K562	1 μM	Function Assay	12 h	enhances the expression of RUNX3 induced by 5-aza-CdR	22179198
Kazumi	1 μM	Apoptosis Assay	24 h	induces cell death	23400519
KG1	1 μM	Apoptosis Assay	24 h	induces cell death	23400519
LM8	0.3 μM	Growth Inhibition Assay	12-96 h	inhibits the cell growth co-treatment with metformin	23451817
LNCaP	100-1000nM	Growth Inhibition Assay	24h	IC50 of 300nM	24854658
Lovo	0.2/1.0/5.0 μM	Growth Inhibition Assay	12/24/36/48 h	induces cell death in concentration- and time-dependent manner	23770000
MCF7	0-600nM	Growth Inhibition Assay	24h	IC50 of 75nM	25192721
MCF7	0.05-2 μM	Function Assay	24 h	reduces the induction of p53-dependent genes by Nutlin-3	23470540
MCF-7	25-400 nM	Growth Inhibition Assay	48 h	IC50 of 220.4nM	23055198
MDA-MB-231	0-600nM	Growth Inhibition Assay	24h	IC50 of 100nM	25192721
MDA-MB-231	25-400 nM	Growth Inhibition Assay	48 h	IC50 of 263.2nM	23055198
MEFs	5μM	Function Assay	16h	increases the EPEC attachment, Tir delivery and the efficiency of pedestal formation	25482634
MFE296	500 nM	Function Assay	5 d	induces L1CAM expression co-treatment with 5-AzaC	23530769
MG-63	0.3 μM	Growth Inhibition Assay	12-96 h	inhibits the cell growth co-treatment with metformin	23451817
MG-63	300 nM	Growth Inhibition Assay	12 h	inhibits the cell growth to 86%	22799338
MG-63	300 nM	Growth Inhibition Assay	24 h	inhibits the cell growth to 67%	22799338
MG-63	300 nM	Growth Inhibition Assay	48 h	inhibits the cell growth to 56%	22799338
NHAC-kn	10/100/500 nM	Growth Inhibition Assay	12 h	IC50 of 500nM	23017871
PC3	0.1μM	Function Assay	48h	reverses EMT	25434997
PC3	0.1μM	Function Assay	48h	attenuates invasion and migration	25434997
PC3	0.1μM	Function Assay	48h	induces increase of HDAC1 and HDAC2 on Slug genes promoter	25434997
PC3	100-1000nM	Growth Inhibition Assay	24h	IC50 of 300nM	24854658
PMNs	30 nM	Function Assay	48 h	inhibits efferocytosis, HDAC activity and Rac activity	23988617
Reh	0.3/1 μM	Function Assay	12 h	enhances the expression of RUNX3 induced by 5-aza-CdR	22179198
RPE	0.2/0.4/0.8/1 μM	Growth Inhibition Assay	24/48/72 h	inhibits the proliferation by cell cycle arrest	24456602
SCC-6	200-3200 nM	Growth Inhibition Assay	12/24/48 h	inhibits the proliferation of SCC-6 cells in a dose- and time-dependent manner	22552321
SH-SY5Y	250 nM	Function Assay	16 h	changes expression pattern of genes involved in cholesterol synthesis, uptake and efflux	23326422
SKOV3	0.05-2 μM	Growth Inhibition Assay	10/24/48 h	mediates growth arrest in a concentration- and time-dependent manner	24223801
SKOV-3	1-10μM	Growth Inhibition Assay	24h	IC50 of 5.6μM	25169491
SKOV-3	0.1-1μM	Growth Inhibition Assay	48h	IC50 of 0.7μM	25169491
SKOV-3	0.01-0.9μM	Growth Inhibition Assay	72h	IC50 of 0.32μM	25169491
SRA01/04	0.2 μM	Growth Inhibition Assay	48 h	suppresses cell proliferation through suppressing the PI3K/Akt, p38MAPK and ERK1/2 signaling pathways	24157878
SRA01/04	0.4/0.8 μM	Growth Inhibition Assay	48 h	induces cell apoptosis	24157878
SUM149PT	2/7.5/10 μM	Growth Inhibition Assay	48 h	induces cell death at 2 μM insensitively	23792638
SUM190PT	50/100/250 nM	Growth Inhibition Assay	48 h	induces cell death at 50 nM sensitively	23792638
SW480	0.1μM	Function Assay	48h	reverses EMT	25434997
SW480	0.1μM	Function Assay	48h	attenuates invasion and migration	25434997
SW480	0.1μM	Function Assay	48h	induces increase of HDAC1 and HDAC2 on Slug genes promoter	25434997
TE13	0.3μM	Function Assay	24h	up-regulates RASSF5A level	25579665
TE13	0.3μM	Apoptosis Assay	24h	inhibits the cell proliferation	25579665
THP1	1 μM	Apoptosis Assay	24 h	induces cell death	23400519
U373	0.25/0.5/1 μM	Function Assay	24 h	increases PR-B expression co-treatment with 5AzadC	23474171
U87	100-300 ng	Growth Inhibition Assay	24 h	inhibits the cell growth to 72% at 200ng	22270849
U87 GBM	100/300/500 nM	Growth Inhibition Assay	72 h	reduces mean cell number by 31, 54, and 58 %	24464841
U87 GBM	100/500 Nm	Function Assay	48 h	Induces Senescence-Like Alterations in Nuclear Morphology	24464841
U937	150-350 nM	Growth Inhibition Assay	24 h	increases cell apoptosis when concentrations higher than 250 nM	22753739

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03049124	Rectal Cancer	Not Applicable	Recruiting	July 31, 2019	Canada, Ontario ... 展开 >> University of Ottawa Recruiting Ottawa, Ontario, Canada, K1N 6N5 Contact: Amanda Wurz, MSc 613-562-5800 ext 3626 amanda.wurz@uottawa.ca 收起 <<
NCT02152267	Craniomandibular Disorders	Not Applicable	Completed	-	Brazil ... 展开 >> Federal University of Bahia Salvador, Bahia, Brazil, 40110-902 收起 <<
NCT01028014	Urethral Sphincter Activity	Not Applicable	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham, The Kirklin Clinic Birmingham, Alabama, United States, 35233 收起 <<
NCT01028014	-		Completed	-	-
NCT03016728	Adolescent and Young Adult Can... 展开 >>cer Survivors 收起 <<	Not Applicable	Recruiting	February 2019	Canada, Ontario ... 展开 >> University of Ottawa Recruiting Ottawa, Ontario, Canada, K1N 6N5 Contact: Amanda Wurz, MSc 613-562-5800 ext 3626 amanda.wurz@uottawa.ca 收起 <<
NCT01974726	Eustachian Tube Dysfunction	Not Applicable	Recruiting	July 2019	United States, Pennsylvania ... 展开 >> University of Pittsburgh Middle Ear Physiology Laboratory Recruiting Pittsburgh, Pennsylvania, United States, 15213 Sub-Investigator: Cuneyt M Alper, MD Sub-Investigator: Margaretha L Casselbrant, MD, PhD Sub-Investigator: Charles D Bluestone, MD Sub-Investigator: Ellen M Mandel, MD Sub-Investigator: Douglas J Swarts, PhD Sub-Investigator: Miriam S Teixeira, MD 收起 <<
NCT03561688	Rheumatoid Arthritis ... 展开 >> Rheumatoid Arthritis of Foot (Disorder) 收起 <<	Not Applicable	Recruiting	April 1, 2020	Denmark ... 展开 >> King Christian X's Hospital for Rhuematic Diseases Recruiting Gråsten, Denmark, 6300 Contact: Kim Hørslev-Petersen, MD, Phd Department for Rheumatology Recruiting Hjørring, Denmark, 9800 Contact: Marcin R Kowalski, MD, Phd 收起 <<
NCT01853215	Intraosseous Vascular Access	Not Applicable	Completed	-	United States, Texas ... 展开 >> Bulverde-Spring Branch EMS Spring Branch, Texas, United States, 78070 收起 <<
NCT01898208	-		Completed	-	-
NCT01853215	-		Completed	-	-
NCT00168454	Overactive Bladder ... 展开 >> Urinary Incontinence 收起 <<	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> Pittsburgh, Pennsylvania, United States Belgium Ghent, Belgium Canada, British Columbia Victoria, British Columbia, Canada Germany Berlin, Germany Poland Warsaw, Poland United Kingdom Sheffield, United Kingdom 收起 <<
NCT01898208	Bacteremia Fu... 展开 >>ngemia Bloodstream Infection 收起 <<	Not Applicable	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 收起 <<
NCT00168454	-		Completed	-	-
NCT00499460	-		Completed	-	-
NCT01332513	Epilepsy	Phase 1	Completed	-	United States, Maryland ... 展开 >> GSK Investigational Site Baltimore, Maryland, United States, 21225 收起 <<
NCT03636035	Mild Knee Osteoarthritis	Not Applicable	Not yet recruiting	December 31, 2019	-
NCT02013375	Sickle Cell Disease	Phase 2	Active, not recruiting	October 1, 2018	United States, Illinois ... 展开 >> University of Illinois Cancer Center Chicago, Illinois, United States, 60612 收起 <<
NCT00499460	Healthy, No Evidence of Diseas... 展开 >>e 收起 <<	Phase 4	Completed	-	United States, Washington ... 展开 >> Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 收起 <<
NCT02638493	-		Completed	-	-
NCT03490162	Malaria	Phase 1	Recruiting	June 4, 2019	United States, North Carolina ... 展开 >> Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit Recruiting Durham, North Carolina, United States, 27710 收起 <<
NCT00916721	Smoking Cessation	Phase 3	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital - Center For Addiction Medicine Boston, Massachusetts, United States, 02114 收起 <<
NCT03514316	Orthodontic Appliance Complica... 展开 >>tion Gingival Overgrowth 收起 <<	Not Applicable	Completed	-	Italy ... 展开 >> Department of Orthodontics, Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata". Roma, Italy, 00133 收起 <<
NCT02638493	-		Completed	-	United States, North Carolina ... 展开 >> University of North Carolina Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT00916721	-		Completed	-	-
NCT01582503	Asthma	Phase 2	Completed	-	-
NCT00311376	Overactive Bladder	Phase 3	Completed	-	United States, Michigan ... 展开 >> Royal Oak, Michigan, United States Australia, New South Wales Randwick, New South Wales, Australia Austria Innsbruck, Austria Belgium Gent, Belgium Canada Sherbrooke, Canada Czech Republic Ostrava, Czech Republic France Garches, France Germany Halle (Saale), Germany New Zealand Christchurch, New Zealand Poland Wroclaw, Poland Russian Federation Moscow, Russian Federation Slovakia Martin, Slovakia Ukraine Lviv, Ukraine United Kingdom London, United Kingdom 收起 <<
NCT00096850	HIV Infections ... 展开 >> Tuberculosis 收起 <<	Not Applicable	Completed	-	United States, California ... 展开 >> Stanford CRS Palo Alto, California, United States, 94305-5107 United States, Ohio The Ohio State Univ. AIDS CRS Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt Therapeutics CRS Nashville, Tennessee, United States, 37203 收起 <<
NCT00461292	Overactive Bladder	Phase 3	Completed	-	United States, Connecticut ... 展开 >> Middlebury, Connecticut, United States Brazil Rio de Janeiro, Brazil Canada, British Columbia Victoria, British Columbia, Canada France Salouel, France Italy Milan, Italy Netherlands Amsterdam, Netherlands Portugal Porto, Portugal Singapore Singapore, Singapore South Africa Pretoria, South Africa Spain Tenerife, Spain Taiwan Hualien, Taiwan United Kingdom Scunthorpe, United Kingdom 收起 <<
NCT01865760	Obesity Hypog... 展开 >>lycemia Surgery 收起 <<	Not Applicable	Unknown	March 2016	Denmark ... 展开 >> Department of Endocrinology, Aarhus University Hospital Recruiting Aarhus C, Denmark, 8000 Contact: Joan Bach Nielsen, Dr 0045+24818454 joanni@rm.dk Sub-Investigator: Joan Bach Nielsen, MD 收起 <<
NCT00467753	Autism	Not Applicable	Completed	-	United States, New Jersey ... 展开 >> Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS Piscataway, New Jersey, United States, 08854 收起 <<
NCT00035425	Febrile Neutropenia	Phase 3	Completed	-	-
NCT02706535	Drug Interactions	Phase 1	Completed	-	United States, Maryland ... 展开 >> GSK Investigational Site Baltimore, Maryland, United States, 21225 收起 <<
NCT00311376	-		Completed	-	-
NCT00263211	Breast Neoplasms	Phase 2	Terminated(Stopped due to low ... 展开 >>percentage of patients with detectable CTCs at baseline.) 收起 <<	-	United States, Missouri ... 展开 >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 收起 <<
NCT00263211	-		Terminated(Stopped due to low ... 展开 >>percentage of patients with detectable CTCs at baseline.) 收起 <<	-	-
NCT03604159	Opioid Dependence	Phase 4	Not yet recruiting	August 2020	-
NCT02237586	Plasmodium Falciparum Malaria ... 展开 >> Malaria 收起 <<	Phase 1	Completed	-	Gabon ... 展开 >> Centre de Recherches Médicales de Lambaréné Lambaréné, Gabon, BP 118 收起 <<
NCT00461292	-		Completed	-	-
NCT03601663	Physical Activity	Not Applicable	Recruiting	August 2019	Canada, Ontario ... 展开 >> University of Ottawa Recruiting Ottawa, Ontario, Canada, K1N6N5 Contact: Jennifer Brunet, PhD (613) 562-5800 ext 3068 jennifer.brunet@uottawa.ca Contact: Melissa Black, BA (613) 562-5800 ext 7300 melissa.black@uottawa.ca 收起 <<
NCT01756404	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> Miramar, Florida, United States 收起 <<
NCT01783704	Hip Fracture	Not Applicable	Completed	-	United States, Connecticut ... 展开 >> University of Connecticut Health Center Farmington, Connecticut, United States, 06030 United States, Maryland University of Maryland, Baltimore Baltimore, Maryland, United States, 21201 United States, New Hampshire Dartmouth Medical School Lebanon, New Hampshire, United States, 03756 United States, Pennsylvania Arcadia University Glenside, Pennsylvania, United States, 19038-3295 收起 <<
NCT03135132	Visceral Fat ... 展开 >>Weight Loss 收起 <<	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Yonsei University Seoul, Korea, Republic of, 03722 收起 <<
NCT00467753	-		Completed	-	-
NCT02506140	Stroke Ischem... 展开 >>ic Attack, Transient 收起 <<	Phase 2 Phase 3	Active, not recruiting	March 10, 2018	China, Fujian ... 展开 >> The First Affiliated Hospital of Fujian Medical University Fuzhou, Fujian, China, 350005 China, Guangdong The Second People's Hospital of Shenzhen Shenzhen, Guangdong, China, 518000 China, Hebei The Second Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050000 North China University of Science And Technology Affiliated Hospital Tangshan, Hebei, China, 063000 Tangshan Gongren Hospital Tangshan, Hebei, China, 063000 China, Henan The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China, 450052 China, Hubei Wuhan Brain Hospital,General Hospital of The Yangtze River Shipping Wuhan, Hubei, China, 430014 Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan, Hubei, China, 430022 Wuhan No.1 Hospital Wuhan, Hubei, China, 430022 Renmin Hospital of Wuhan University Wuhan, Hubei, China, 430060 China, Hunan Xiangya Hospital Central South University Changsha, Hunan, China, 410008 China, Jiangsu Northern Jiangsu People's Hospital,Clinical Medical School,YangZhou University Yangzhou, Jiangsu, China, 225001 China, Liaoning General Hospital of Shenyang Military Shengyang, Liaoning, China, 110016 China, Shanxi The Second Hospital of Shanxi Medical University Taiyuan, Shanxi, China, 030001 General Hospital of TISCO Taiyuan, Shanxi, China, 030003 China, Zhejiang Taizhou First People's Hospital,Huangyan Hospital of Wenzhou Medical University Taizhou, Zhejiang, China, 318020 The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang, China, 325000 Wenzhou Hospital of integrated Chinese and Western medicine Wenzhou, Zhejiang, China, 325000 China Aviation General Hospital of China Medical University Beijing, China, 100012 Beijing Tian Tan Hospital, Capital Medical University Beijing, China, 100050 Dongfang Hospital Beijing University of Chinese Medicine Beijing, China, 100078 The First Hospital of Fangshan District,Beijing Beijing, China, 102400 Daping Hospital,Third Military Medical University Chongqing, China, 400042 Renji Hospital,Shanghai Jiao Tong University School of Medicine Shanghai, China, 200127 Tianjin Huanhu Hospital Tianjin, China, 300350 收起 <<
NCT02869009	Ischemic Stroke	Early Phase 1	Recruiting	April 30, 2020	China, Liaoning ... 展开 >> General Hospital of Shenyang Military Region Recruiting Shenyang, Liaoning, China Contact: Hui-Sheng Chen 86-24-28897511 chszh@aliyun.com Contact: Xin-hong Wang 86-15309885658 450341972@qq.com 收起 <<
NCT02225886	Anaemia Response to the Treatm... 展开 >>ent Peripheral Iron Indices Oxalemia 收起 <<	Phase 4	Not yet recruiting	December 2021	Romania ... 展开 >> "Nefrolab" Dialysis Center Not yet recruiting Slatina, Romania Contact: Aurelian Simionescu, MD, PhD +40732161768 relusimionescu@yahoo.com Contact: Ileana Mihailescu, MD +40730577485 dr_ilemih@yahoo.com 收起 <<
NCT02523599	Pain, Postoperative	Phase 3	Completed	-	United States, Alabama ... 展开 >> Mobile, Alabama, United States, 36617 Sheffield, Alabama, United States, 35660 United States, Arizona Phoenix, Arizona, United States, 85023 United States, Arkansas Little Rock, Arkansas, United States, 72205 United States, California Encino, California, United States, 91436 United States, Florida Bradenton, Florida, United States, 34206 Clermont, Florida, United States, 34711 Inverness, Florida, United States, 34452 Kissimmee, Florida, United States, 34741 Miami, Florida, United States, 33136 Miami, Florida, United States, 33144 Orlando, Florida, United States, 32825 St. Petersberg, Florida, United States, 33713 Tampa, Florida, United States, 33606 Weston, Florida, United States, 33331 United States, Indiana Indianapolis, Indiana, United States, 46202 United States, Massachusetts Springfield, Massachusetts, United States, 01199 United States, Michigan Flint, Michigan, United States, 48532 United States, Nevada Las Vegas, Nevada, United States, 89102 Las Vegas, Nevada, United States, 89106 United States, Texas El Paso, Texas, United States, 79935 Houston, Texas, United States, 77054 Lampasas, Texas, United States, 76550 收起 <<
NCT00979589	Stroke Transi... 展开 >>ent Ischemic Attack 收起 <<	Phase 3	Completed	-	China ... 展开 >> Beijing Tian Tan Hospital, Capital Medical University Beijing, China, 100050 收起 <<
NCT02525133	Pain, Postoperative	Phase 3	Completed	-	-
NCT00817999	-		Completed	-	-
NCT02992639	Visceral Fat ... 展开 >>Liver Dysfunction 收起 <<	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Yonsei University Seoul, Korea, Republic of, 03722 收起 <<
NCT01133210	Hypertriglyceridemia	Phase 1	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 收起 <<
NCT00734162	Hepatitis B Virus (HBV)	Phase 3	Completed	-	United States, California ... 展开 >> Children's Hospital & Research Center at Oakland Oakland, California, United States, 94609 United States, Indiana Riley Hospital for Children Indianapolis, Indiana, United States, 46202 United States, Washington Children's Hospital & Regional Medical Center, d/b/a Seattle Children's Research Institute Seattle, Washington, United States, 98105 Bulgaria Multiprofile Hospital for Active Treatment Sveti Georgi Plovdiv, Bulgaria, 4002 Clinic of Gastroenterology, Specialized Hospital for Active Treatment of Pediatric Diseases, Sofia Sofia, Bulgaria, 1606 France Hopital Femmes Meres Enfants Bron Cedex, France, 69677 Hôpital Claude Huriez Lille Cedex, France, 59037 Poland Samodzielny Publiczny Dzieciecy Szpital Kliniczny Akademii Medycznej w Bialymstoku Białystok, Poland, 15-274 Wojewodzki Specjalistyczny Szpital im Bieganskiego Bydgoszcz, Poland, 85-030 Wojewodzki Szpital Obserwacyjno-Zakazny im. T. Browicza Bydgoszcz, Poland, 85-030 Krakowski Szpital Specjalistyczny im. Jana Pawla II Kraków, Poland, 31-202 Samodzielny Publiczny Szpital Kliniczny im. Karola Johschera Poznan, Poland, 60-572 Specjalistyczny Zespol Opieki Zdrowotnej nad Matka i Dzieckiem Poznań, Poland, 61-734 Wojewodzki Szpital Zakazny Warszawa, Poland, 01-201 Samodzielny Publiczny Szpital Kliniczny Nr 1 Wrocław, Poland, 50-368 Romania Fundeni Clinical Institute Bucharest, Romania, 022328 Institute for Infectious Diseases Bucharest, Romania, 21105 Cluj Childrens Emergency Hospital Napaco, Romania, 400217 Spain Hosp Univ y Politecnico La Fe de Valencia Madrid, Spain, 28046 Hospital Universitario De Getafe Madrid, Spain, 46009 Turkey Ege Universitesi Tip Fakultesi Hastanesi Izmir, Turkey, 35100 收起 <<
NCT02986815	Glioma	Not Applicable	Recruiting	December 2021	United States, Texas ... 展开 >> University of Texas Southwestern Medical Center Recruiting Dallas, Texas, United States, 75063 Contact: Sarh McNeil, RN 214-645-8166 sarah.mcneil@utsouthwestern.edu Principal Investigator: Robert Bachoo, MD 收起 <<
NCT03653546	Non-small Cell Lung Cancer ... 展开 >> EGFR Gene Mutation Brain Metastases 收起 <<	Phase 2 Phase 3	Recruiting	October 16, 2021	-
NCT00734162	-		Completed	-	-
NCT01808040	Post Menopausal, Hormone Recep... 展开 >>tor Positive Breast Cancer 收起 <<	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> University of Wisconsin Madison, Wisconsin, United States, 53792 收起 <<
NCT01663194	-		Completed	-	Turkey ... 展开 >> Erciyes University school of medicine Kayseri, Turkey, 38039 收起 <<
NCT02642133	Ankyloglossia ... 展开 >> Breastfeeding 收起 <<	Not Applicable	Completed	-	-
NCT00501540	Neuroendocrine Tumors	Phase 2	Completed	-	United States, Wisconsin ... 展开 >> University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 收起 <<
NCT01091727	Neurogenic Detrusor Overactivi... 展开 >>ty 收起 <<	Phase 3	Completed	-	Canada, Ontario ... 展开 >> Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 收起 <<
NCT03201952	Glucose Intolerance ... 展开 >> Gastric Bypass Surgery 收起 <<	Phase 1	Recruiting	July 1, 2019	United States, Tennessee ... 展开 >> Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Michael Dole, MD 864-616-1389 michael.dole@vanderbilt.edu 收起 <<
NCT02590549	Keratoconus	Not Applicable	Completed	-	-
NCT00520468	Myelodysplastic Syndrome	Phase 2	Completed	-	United States, Texas ... 展开 >> U.T.M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00520468	-		Completed	-	-
NCT03483402	Pseudoexfoliation Glaucoma ... 展开 >> Primary Open-angle Glaucoma 收起 <<	Not Applicable	Completed	-	-
NCT01916785	Chronic Myelogenous Leukemia, ... 展开 >>BCR/ABL Positive 收起 <<	Phase 2	Completed	-	Canada ... 展开 >> Southern Alberta Cancer Research Institute Calgary, Canada Hôpital Charles LeMoyne Greenfield Park, Canada Queen elisabeth II Health Sciences Center Halifax, Canada CH Pierre LeGardeur Lachenaie, Canada Moncton City Hospital Moncton, Canada Hôpital Général Juif - Sir. Mortimer B. Davis Montréal, Canada Hôpital Maisonneuve-Rosemont Montréal, Canada Hôpital Royal Victoria Montréal, Canada Hôpital de l'Enfant Jésus - Centre hospitalier affilié universitaire de Québec Québec, Canada Pavillon Hôtel-Dieu de Québec - Centre hospitalier universitaire de Québec Québec, Canada France CHU Angers Angers, France Hôpital Avicenne Bobigny, France Institut Bergonie Bordeaux, France Hopital MORVAN Brest, France CH René Dubos Cergy Pontoise, France Hôpital d'Instruction de Armées Percy Clamart, France Hopital Henri MONDOR Creteil, France Hôpital Claude Huriez Lille, France CH Lyon Sud Lyon, France Institut Paoli-Calmettes Marseille, France Hôpital d'Annecy Metz Tessy, France C.H.U. Brabois Nancy, France CHU Hoptel dieu Nantes, France Hôpital l'Archet 1 Nice, France CHU Caremeau Nimes, France Hopital Saint Louis Paris, France Hôpital Necker-Enfants Malades Paris, France Hôpital St Antoine Paris, France CHU Poitiers Poitiers, France CHU Rennes - Pontchaillou Rennes, France Centre René Huguenin Saint Cloud, France Hôpital Purpan Toulouse, France CHRU Bretonneau Tours, France Central Hospital Versailles, France 收起 <<
NCT01083108	Obesity Baria... 展开 >>tric Surgery Morbid Obesity Diabetes Mellitus Type 2 Diet Therapy 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> University of Maryland, Baltimore Baltimore, Maryland, United States, 21201-1595 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 收起 <<
NCT02189889	Anemia Cardio... 展开 >>vascular Disease 收起 <<	Phase 1 Phase 2	Recruiting	June 2020	United States, Texas ... 展开 >> Clements University Hospital Recruiting Dallas, Texas, United States, 75390-8894 Contact: Kenni Landgraf, RN, BSN 214-645-8087 kenni.landgraf@utsouthwestern.edu Contact: Veronna Bell 214-645-8018 veronna.bell@utsouthwestern.edu Principal Investigator: Philip E. Greilich, MD Sub-Investigator: Michael Wait, MD Sub-Investigator: Eric Rosero, MD Sub-Investigator: Pietro Bajona, MD Sub-Investigator: Burner James, MD Clements University Hospital Recruiting Dallas, Texas, United States, 75390 Contact: Kenni Landgraf, RN, BSN 214-645-8087 kenni.landgraf@utsouthwestern.edu 收起 <<
NCT02913170	Hypercholesterolemia	Phase 4	Completed	-	Korea, Republic of ... 展开 >> Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University. Seoul, Korea, Republic of, 120-749 收起 <<
NCT00404053	Acute Coronary Syndrome	Phase 4	Completed	-	-
NCT02923700	Osteoarthritis	Phase 4	Recruiting	December 2020	Italy ... 展开 >> Rizzoli Orthopaedic Institute Recruiting Bologna, Emilia Romagna, Italy, 40136 Contact: Elizaveta Kon, MD +39 0516366567 e.kon@biomec.ior.it Contact: Giuseppe Filardo, MD +39 0516366567 g.filardo@ior.it 收起 <<
NCT00644657	Coronary Artery Disease ... 展开 >> Chest Pain 收起 <<	Not Applicable	Completed	-	United States, Oklahoma ... 展开 >> VA Medical Center, 1F187 Oklahoma City, Oklahoma, United States, 73104-5076 收起 <<
NCT00644657	-		Completed	-	-
NCT01111864	Bacterial Infections	Not Applicable	Completed	-	Kenya ... 展开 >> Kikoneni Clinic Kikoneni, Kwale district, Kenya 收起 <<
NCT02184637	Malaria, Vivax	Phase 1	Completed	-	United States, Maryland ... 展开 >> GSK Investigational Site Baltimore, Maryland, United States, 21225 收起 <<
NCT03413150	-		Completed	-	-
NCT01149629	Symptomatic Neurogenic Orthost... 展开 >>atic Hypotension 收起 <<	Phase 1	Completed	-	United States, North Dakota ... 展开 >> Cetero Research Fargo, North Dakota, United States, 58104 收起 <<
NCT02557685	Clostridium Difficile Infectio... 展开 >>n 收起 <<	Phase 2	Unknown	March 2017	United States, Rhode Island ... 展开 >> The Miriam Hospital Recruiting Providence, Rhode Island, United States, 02906 Contact: Colleen R. Kelly, MD 401-793-7080 ckelly2@lifespan.org Contact: Patrizia Curran, MD 401-793-7824 pcurran1@lifespan.org Principal Investigator: Colleen R. Kelly, MD 收起 <<
NCT00320307	HIV Infection	Phase 1	Completed	-	United Kingdom ... 展开 >> GSK Investigational Site London, United Kingdom, SW10 9TH 收起 <<
NCT02562014	Obesity	Not Applicable	Completed	-	-
NCT03504774	Food Allergy	Phase 2	Not yet recruiting	March 10, 2026	-
NCT01146301	Carotid Stenosis	Phase 4	Completed	-	Netherlands ... 展开 >> St-Antonius Ziekenhuis Nieuwegein, Utrecht, Netherlands, 3435CM 收起 <<
NCT01443169	Healthy	Phase 1	Completed	-	Belgium ... 展开 >> Pfizer Investigational Site Bruxelles, Belgium, B-1070 收起 <<
NCT00882739	Acute Myocardial Infarction	Phase 4	Completed	-	Italy ... 展开 >> Cardiovascular Department, Ospedale S.Donato Arezzo, AR, Italy, 52100 收起 <<
NCT00439140	Overactive Bladder	Phase 3	Terminated(In agreement with F... 展开 >>DA the study was terminated based on data available.) 收起 <<	-	United States, Pennsylvania ... 展开 >> Philadelphia, Pennsylvania, United States Australia, Queensland Herston, Queensland, Australia Canada, British Columbia Victoria, British Columbia, Canada India Chennai, India 收起 <<
NCT03362723	Solid Tumors	Phase 1	Active, not recruiting	March 29, 2019	United States, Colorado ... 展开 >> University of Colorado Aurora, Colorado, United States, 80045-2517 United States, Connecticut Yale Cancer Center; Medical Oncology New Haven, Connecticut, United States, 06520 United States, Missouri Washington University; Wash Uni. Sch. Of Med Saint Louis, Missouri, United States, 63110 United States, Nevada Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley Las Vegas, Nevada, United States, 89169 United States, Oklahoma University of Oklahoma Health Sciences Center; Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee New Orleans Center for Clinical Research Knoxville, Tennessee, United States, 37920 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75230 Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Oncology Associates Norfolk, Virginia, United States, 23502 Canada, Ontario Princess Margaret Cancer Center Toronto, Ontario, Canada, M5G 1Z5 Canada, Quebec Jewish General Hospital / McGill University Montreal, Quebec, Canada, H3T 1E2 收起 <<
NCT00817999	Healthy	Phase 4	Completed	-	United States, Nebraska ... 展开 >> Creighton Cardiac Center Omaha, Nebraska, United States, 68131 收起 <<
NCT03329001	Solid Tumor	Phase 1	Recruiting	December 2019	United States, California ... 展开 >> California Cancer Center for Research Excellence cCARE Recruiting Encinitas, California, United States, 92024 Principal Investigator: Alberto Bessudo, MD United States, Georgia Winship Cancer Institute of Emory University Recruiting Atlanta, Georgia, United States, 30322 Principal Investigator: R. Donald Harvey, PharmD United States, Tennessee Tennesse Oncology (SCRI) Recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Erika Hamilton, MD United States, Texas MD Anderson Recruiting Houston, Texas, United States, 77030 Principal Investigator: Sarina Piha-Paul, MD START- South Texas Accelerated Research Therapeutics, LLC Recruiting San Antonio, Texas, United States, 78229 Principal Investigator: Amita Patnaik, MD 收起 <<
NCT02098174	Glomerular Filtration Rate ... 展开 >> Acute Kidney Injury 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> University of Maryland Baltimore, Maryland, United States, 21201 收起 <<
NCT01080612	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT03759067	Angina, Stable	Not Applicable	Completed	-	-
NCT00631345	Prediabetes O... 展开 >>besity 收起 <<	Not Applicable	Completed	-	United States, North Carolina ... 展开 >> Wake Forest University School of Medicine Winston-Salem, North Carolina, United States, 27157 收起 <<
NCT01869465	Schistosomiasis	Not Applicable	Unknown	June 2013	Uganda ... 展开 >> Primary schools Jinja, Uganda 收起 <<
NCT00559260	-		Completed	-	United States, Oklahoma ... 展开 >> Oklahoma Foundation for Digestive Research Oklahoma City, Oklahoma, United States 收起 <<
NCT01664702	Childhood Obesity	Not Applicable	Completed	-	United States, Kansas ... 展开 >> Energy Balance Lab, The University of Kansas Lawrence, Kansas, United States, 66045 收起 <<
NCT01575054	Muscle Spasticity	Phase 3	Completed	-	United States, California ... 展开 >> Downey, California, United States United States, Florida Daytona Beach, Florida, United States Canada, Quebec Montreal, Quebec, Canada Czech Republic Prague, Czech Republic Germany Wiesbaden, Germany Würzburg, Germany Hungary Budapest, Hungary Korea, Republic of Gyeonggi-Do, Korea, Republic of Poland Krakow, Poland Russian Federation Krasnoyarsk, Russian Federation United Kingdom Stoke-on-Trent, England, United Kingdom Fazakerley, Liverpool, United Kingdom 收起 <<
NCT01575054	-		Completed	-	-
NCT00276198	Iron Deficiency Anemia ... 展开 >> Infectious Diseases Undernutrition 收起 <<	Phase 3	Completed	-	Israel ... 展开 >> Ministry of Health Beer-Sheva, Israel, 10050 收起 <<
NCT00823290	Hepatocellular Carcinoma	Phase 1	Unknown	December 2010	Germany ... 展开 >> Department of Medicine 1, University Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Matthias Ocker, MD +49-6421-58 ext 68931 Matthias.Ocker@staff.uni-marburg.de Contact: Susanne Gahr, MD +49-9131-85 ext 35000 susanne.gahr@uk-erlangen.de Principal Investigator: Deike Strobel, MD 收起 <<
NCT00284518	Benign Prostatic Hyperplasia	Phase 2	Completed	-	Australia ... 展开 >> Murdoch, Australia Austria Vienna, Austria Canada, British Columbia Victoria, British Columbia, Canada Czech Republic Olomouc, Czech Republic France Paris Cedex 13, France Germany Braunschweig, Germany Italy Perugia, Italy Korea, Republic of Seoul, Korea, Republic of Slovakia Martin, Slovakia Taiwan Taipei, Taiwan United Kingdom London, United Kingdom 收起 <<
NCT00284518	-		Completed	-	-
NCT00821834	Stable Angina ... 展开 >> Myocardial Infarction 收起 <<	Phase 3	Completed	-	Japan ... 展开 >> Sanofi-Aventis Administrative Office Tokyo, Japan 收起 <<
NCT00834912	Healthy	Phase 1	Completed	-	-
NCT00501540	-		Completed	-	-
NCT01901198	Healthy Volunteers	Phase 1	Completed	-	China, Beijing ... 展开 >> Beijing YouAn Hospital, Capital Medical University Beijing, Beijing, China, 100069 收起 <<
NCT02004821	Individuals With Constitutiona... 展开 >>l Thinness 收起 <<	Not Applicable	Completed	-	France ... 展开 >> CHU de Saint-Étienne St-Etienne, France, 42055 收起 <<
NCT00439140	-		Terminated(In agreement with F... 展开 >>DA the study was terminated based on data available.) 收起 <<	-	-
NCT01157000	Healthy	Phase 1	Completed	-	Belgium ... 展开 >> Merksem, Belgium 收起 <<
NCT00834912	-		Completed	-	-
NCT03066401	-		Terminated(insufficient inclus... 展开 >>ion rate) 收起 <<	-	France ... 展开 >> Hôpital Roger Salengro, CHRU de Lille Lille, France 收起 <<
NCT01703494	Clostridium Difficile	Phase 2	Unknown	September 2015	United States, New York ... 展开 >> Montefiore Medical Center The Bronx, New York, United States, 10467 United States, Rhode Island The Miriam Hospital Providence, Rhode Island, United States, 02906 收起 <<
NCT00876447	Overactive Bladder	Phase 3	Completed	-	-
NCT03066414	-		Completed	-	France ... 展开 >> Hôpital Roger Salengro, CHRU de Lille Lille, France 收起 <<
NCT02910635	Abnormalities, Cardiovascular	Phase 1	Completed	-	United States, Texas ... 展开 >> Covance Dallas, Texas, United States, 75247 收起 <<
NCT00876447	-		Completed	-	-

靶点	HDAC HDAC, IC50:~1.8 nM
描述	HDACs are a group of enzymes that remove acetyl groups and regulate the histone tail, protein-DNA interaction, chromatin conformation, and even transcription. There are 18 mammalian HDACs divided into four classes: class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10), class III (sirtuin family: sirt1-sirt7) and class IV (HDAC11)^[1]. Trichostatin A (TSA) is the inhibitors of the class I and class II HDACs with IC50 value of 2.4 ± 0.5 nM (measured by HDAC activity in cellular extracts). Trichostatin A treatment with concentration of 2 μM for 24h can increase histone H4 hyperacetylation in all of the breast cancer cell lines tested (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3) significantly and inhibit the cell growth with IC50 values ranging in 26 – 308 nM in 96h. Treatment of 500 μg/kg trichostatin A by s.c injection daily for 4 weeks significantly inhibited tumor growth in Ludwig/Wistar/Olac female rats bearing tumors induced with NMU, compared with control^[2]. Trichostatin A is usually used in the study of tumor growth inhibition. The cell death and cell cycle arrest induced by it may involve in several mechanisms including transcription-dependence and -independence, such as cell cycle arrest, apoptosis, the regulation of ROS and the inhibition of angiogenesis^[3].
作用机制	Trichostatin A comprises a hydroxamic acid-based metal-binding domain that coordinates the catalytic Zn(II) in the HDAC active site^[4].

CAS号	58880-19-6
分子式	C₁₇H₂₂N₂O₃
分子量	302.37
SMILES Code	CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
MDL No.	MFCD03848392

别名	曲古柳菌素A ;TSA
运输	蓝冰
InChI Key	RTKIYFITIVXBLE-QEQCGCAPSA-N
Pubchem ID	444732

Trichostatin A/曲古抑菌素A {[allProObj[0].p_purity_real_show]}

Trichostatin A/曲古抑菌素A 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Trichostatin A/曲古抑菌素A 质控信息

Trichostatin A/曲古抑菌素A 生物活性

Trichostatin A/曲古抑菌素A 细胞实验

Trichostatin A/曲古抑菌素A 动物实验

Trichostatin A/曲古抑菌素A 动物研究

Trichostatin A/曲古抑菌素A 临床研究

Trichostatin A/曲古抑菌素A 参考文献

Trichostatin A/曲古抑菌素A 实验方案

Trichostatin A/曲古抑菌素A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Trichostatin A/曲古抑菌素A {[allProObj[0].p_purity_real_show]}

Trichostatin A/曲古抑菌素A 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Trichostatin A/曲古抑菌素A 质控信息

Trichostatin A/曲古抑菌素A 生物活性

Trichostatin A/曲古抑菌素A 细胞实验

Trichostatin A/曲古抑菌素A 动物实验

Trichostatin A/曲古抑菌素A 动物研究

Trichostatin A/曲古抑菌素A 临床研究

Trichostatin A/曲古抑菌素A 参考文献

Trichostatin A/曲古抑菌素A 实验方案

Trichostatin A/曲古抑菌素A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Trichostatin A/曲古抑菌素A 纯度/质量文件产品仅供科研